AOD-9604 vs Sermorelin
Head-to-head comparison of AOD-9604 and Sermorelin for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Aod 9604 | Sermorelin |
|---|---|---|
| Category | Metabolic / Fat Loss | Growth Hormone Secretagogue |
| Mechanism | AOD-9604 (C78H123N23O23S2) works through a dual-action mechanism: it accelerates breakdown of stored fat (lipolysis) via cAMP signaling and enzymatic activation (stimulating hormone-sensitive lipase), while simultaneously blocking formation of new fat (lipogenesis). | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. |
| Evidence Rating | C — Phase I–II Clinical Trials | C — Phase I–II Clinical Trials |
| Clinical Status | Clinical development discontinued after Phase 2; GRAS status for food use | Previously FDA-approved (Geref, discontinued); now used off-label via compounding |
| Safety Profile | In extensive clinical trials, side effect profile was virtually indistinguishable from placebo; Mild headaches or flushing reported in small percentage of users | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts) |
| Molecular Weight | ~1815.1 g/mol | ~3357.9 g/mol |
| Half-Life | ~30 minutes | ~10–20 minutes |
Overview
AOD-9604 and Sermorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
AOD-9604 — Mechanism & Evidence
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191 plus an N-terminal tyrosine, Tyr-hGH(177-191)) developed at Monash University, Australia. It retains the lipolytic (fat-burning) properties of HGH while discarding the growth-promoting and diabetogenic effects. The FDA granted it GRAS status for food use in 2014, though clinical development for obesity was discontinued.
Key claims: Promotes fat loss without growth effects; Does not affect blood sugar or IGF-1; May help with cartilage repair.
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
Shared Research Applications
These peptides target different research areas. AOD-9604 focuses on Fat Loss, while Sermorelin targets Anti-Aging, Body Composition, Sleep.
Safety Considerations
AOD-9604: In extensive clinical trials, side effect profile was virtually indistinguishable from placebo Mild headaches or flushing reported in small percentage of users No growth effects: does not increase IGF-1, so zero risk of abnormal bone growth or organ enlargement
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts) Rare: dizziness, hyperactivity, urticaria
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
CJC-1295 vs Sermorelin: Comparing Growth Hormone-Releasing Peptides
Compare CJC-1295 vs Sermorelin for growth hormone release. Analyze mechanisms, preclinical data, and research limitations for these GHRH analogs.
Tesamorelin vs Sermorelin: Comparing GHRH Analogues in Research
Compare tesamorelin vs sermorelin GHRH analogues for research. Explore mechanisms, preclinical findings, and evidence limitations.
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.